Astellas Pharma Gmbh

Jotaro Suzuki

Kentaro Sato

Jun Maeda

Takahiro Ishii

Takashi Sugane

Takatoshi Kanayama

Akio Kakefuda

Tatsuhisa Takahashi

Chikashi Saitoh

Fumie Narazaki

Chisato Kanai

Ryuichi Takezawa

Hitoshi Doihara

Hiroyuki Ito

A novel pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound and its pharmaceutically acceptable salt has a potent FAAH-inhibitory activity. Further, the pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound of the present disclosure is also useful in the treatment of urinary frequency and urinary incontinence, overactive bladder and/or pain.

Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound

To provide a compound usable for treatment of diseases associated with fatty acid amide hydrolase (FAAH), especially for treatment of urinary frequency and urinary incontinence, overactive bladder and/or pain. We have found that a novel pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative and its pharmaceutically acceptable salt has a potent FAAH-inhibitory activity. Further, the pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative of the present invention has an excellent effect for increasing an effective bladder capacity, an excellent effect for relieving urinary frequency and an excellent anti-allodynia effect, and is therefore usable for treatment of urinary frequency and urinary incontinence, overactive bladder and/or pain.

A novel pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound or its pharmaceutically acceptable salt has a potent FAAH-inhibitory activity. Further, the pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound of the present disclosure is also useful in the treatment of urinary frequency and urinary incontinence, overactive bladder and/or pain.

N-(1H-tetrazol-5-yl)-1-phenoxy-4H-quinolizin-4-one-3-carboxamide is effective for treating IBS. In addition, IBS may be effectively treated with N-(1H-tetrazol-5-yl)-1-phenoxy-4H-quinolizin-4-one-3-carboxamide when used concomitantly with at least one of various serotonin 5-HT3 receptor antagonists.

Treatment for irritable bowel syndrome

Growing community of inventors

Tokyo, Japan

Jotaro Suzuki